6CM
PRLD icon

683 Capital Management’s Prelude Therapeutics PRLD Stock Holding History

683 Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-28,631
Closed -$163K – 233
2023
Q1 		$163K Hold
28,631
– – 0.01% 192
2022
Q4 		$173K Buy
+28,631
New +$183K 0.01% 201

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

683 Capital Management's PRLD Position: Q2 2023 in Review

683 Capital Management sold out of Prelude Therapeutics (PRLD) in Q2 2023, closing a stake of 28,631 shares — an estimated $163K sold.

683 Capital Management first reported a position in PRLD in Q4 2022 and held it in 2 quarters. The position peaked at $173K in Q4 2022. 55 funds tracked by Wall St. Rank hold PRLD as of Q2 2023.

  • 683 Capital Management reported no remaining Prelude Therapeutics position as of Q2 2023 after selling out during the quarter.
  • 683 Capital Management sold 28,631 Prelude Therapeutics shares in Q2 2023, an estimated $163K.
  • 683 Capital Management first reported a position in Prelude Therapeutics in Q4 2022 and held it in 2 quarters.
  • 683 Capital Management's Prelude Therapeutics position peaked at $173K in Q4 2022.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.